XNAS · Healthcare · Biotechnology
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | Q1 2026 | -0.17 | -0.30 | -76.47% | $164.9M | ❌ Miss | +1.03% | +9.74% | +49.38% |
| 2026-02-24 | Q4 2025 | 0.31 | 0.20 | -35.48% | $202.1M | ❌ Miss | -1.04% | -3.29% | +5.62% |
| 2025-11-04 |
| Q3 2025 |
| 0.15 |
| 0.16 |
| +6.67% |
| $207.6M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-31 | Q2 2025 | 0.20 | 0.29 | +45.00% | $194.4M | ✅ Beat | -3.25% | +6.42% | +3.80% |
| 2025-02-26 | Q4 2024 | 0.37 | 0.26 | -29.73% | $181.9M | ❌ Miss | -5.55% | -12.43% | -13.79% |
| 2024-10-30 | Q3 2024 | 0.28 | 0.41 | +46.43% | $182.5M | ✅ Beat | +4.44% | +15.65% | +23.01% |
| 2024-07-29 | Q2 2024 | 0.23 | 0.32 | +39.13% | $163.8M | ✅ Beat | -1.12% | -5.53% | -5.72% |
| 2024-05-01 | Q1 2024 | 0.22 | 0.25 | +13.64% | $146.8M | ✅ Beat | +4.94% | +6.37% | +26.34% |
Showing last 8 quarters.